Research programme: combination vaccines - Roche

Drug Profile

Research programme: combination vaccines - Roche

Latest Information Update: 08 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioVeris Corporation
  • Developer Baxter Healthcare Corporation; Roche
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 27 Jun 2007 BioVeris was acquired and merged into Roche
  • 31 Jan 2007 BioVeris and Baxter Healthcare entered into a technology license agreement for N. meningitidis group Y and H. influenzae type b components for use in combination vaccines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top